开发的mRNA疫苗用于连续选择性器官对细胞向质瘤
Lin Shi1, Yueying Li1, Shiyun Huang1
1School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, PR China.
Nature communications
|December 11, 2025
概括
使者RNA (mRNA) 疗法在治疗质瘤方面表现有前途. 新的脂质纳米颗粒 (LNP) 改善了mRNA向特定细胞的传递,提高了治疗效率并减少了副作用.
科学领域:
- 生物技术是生物技术.
- 纳米医学是一种纳米医学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 基于信使RNA (mRNA) 的疗法具有广泛的疾病治疗潜力.
- 目前通过脂质纳米颗粒 (LNP) 传递的全身mRNA主要准肝脏.
- 对mRNA的有效和特定的器官/细胞向仍然是一个重大挑战.
研究的目的:
- 为了研究可电离性脂类物质定位异构对mRNA-LNP活性的影响.
- 开发一种针对肝脏以外的向性全身mRNA输送的新战略.
- 评估针对质瘤的向mRNA疫苗的治疗疗效.
主要方法:
- 合成的meta/ortho/para-ionizable脂类蛋白库. 这是一个很好的方法.
- 制备三组分脂质纳米粒子 (tLNPs) 没有PEG-脂质.
- 实施顺序选择性器官对细胞向 (SSOCT) 进行脏树突细胞输送.
- 在动物体内评估mRNA疫苗在小鼠质瘤模型中的疗效,有或没有Anti-PD-1治疗.
主要成果:
- 与ortho-/para-isomers相比,含有meta-ionizable lipidoid的tLNP (meta-tLNP) 显示出更高的mRNA传递效率.
- 通过SSOCT,可以在脏中选择性mRNA表达,并随后准树突细胞.
- 通过meta-tLNPs传递mRNA疫苗有效治疗小鼠质瘤,特别是在与抗PD-1疗法相结合时.
- 组合疗法导致完全消除质瘤,降低肝毒性,并将过敏反应降到最低.
结论:
- 电离性脂类物质的定位异构显著影响mRNA-LNP传递效率.
- SSOCT是一种可行的策略,用于将向的mRNA输送到脏树突细胞.
- 向mRNA疗法与免疫疗法相结合,为质瘤提供了一种有效且更安全的治疗方法.
更多相关视频
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
8.3K
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
3.0K
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...